Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome (OUTCOV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04365582
Recruitment Status : Not yet recruiting
First Posted : April 28, 2020
Last Update Posted : April 28, 2020
Sponsor:
Information provided by (Responsible Party):
Groupe Hospitalier Paris Saint Joseph

Brief Summary:
COVID-19 is a respiratory disease due to a novel coronavirus (SARS-CoV-2) that causes substantial morbidity and mortality. To date, no treatment has been proved to be effective in COVID-19. Elderly patients and patients with comorbidities have the worse prognosis with a higher risk of hospitalization, ICU admission and death. The efficacy of an early outpatient treatment could be suggested but need to be confirmed. This confirmation is mandatory to improve prognosis of COVID-19 but also to avoid unsuspected deleterious effect of drugs already used in clinical practice but not based on evidence.

Condition or disease Intervention/treatment Phase
COVID Drug: Azithromycin Drug: Hydroxychloroquine Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab Phase 3

Detailed Description:

The investigators make the hypothesis that an early outpatient treatment of COVID among patient with respiratory symptoms and risk factors for poor outcome can improve the prognosis of these patient and decrease the need for hospital admission.

Our study is an open label randomized clinical trial comparing 4 arms of treatment: Standards of Care (SoC) alone versus SoC + Azithromycine versus SoC + Hydroxychloroquine vs Soc + Lopinavir/Ritonavir.

Our involved population is patients more than 50 years of age with comorbidity or patients more than 70 years of age.

Our primary objective is to evaluate the efficacy of early outpatient treatment compared to standard of care in patients COVID-19 with risk factors for poor outcome. The criteria is hospital admission at Day 20 and the hospital admission rate will be compared between groups by a Chi² test or a Fisher's exact test.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 640 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization
Estimated Study Start Date : April 28, 2020
Estimated Primary Completion Date : July 28, 2020
Estimated Study Completion Date : January 28, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Azithromycin
Azithromycin
Drug: Azithromycin
500 mg day 1 ; 250 mg/day for 4 days

Experimental: Hydroxychlororquine
Hydroxychlororquine
Drug: Hydroxychloroquine
200 mg x 3/day for 10 days

Experimental: Lopinavir/Ritonavir
Lopinavir/Ritonavir
Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab
400/100 mg (2 tablets) x 2/day for 15 days
Other Name: Lopinavir/Ritonavir

No Intervention: standards of care
SoC



Primary Outcome Measures :
  1. Hospital admission [ Time Frame: Day 20 ]
    Hospitalization at D20


Secondary Outcome Measures :
  1. Effect of treatment on Death at D20 [ Time Frame: Day 20 ]
    This outcome corresponds to the number of patients who died on day 20.

  2. Effect of treatment on Death at D60 [ Time Frame: Day 60 ]
    This outcome corresponds to the number of patients who died on day 60.

  3. Effect of treatment on Death due to COVID at D20 [ Time Frame: Day 20 ]
    This outcome corresponds to the number of patients who died due to COVID on day 20.

  4. Effect of treatment on Death due to COVID at D60 [ Time Frame: Day 60 ]
    This outcome corresponds to the number of patients who died due to COVID on day 60.

  5. Effect of treatment on need for ICU stay at D20 [ Time Frame: Day 20 ]
    This outcome corresponds to the number of participants who need ICU stay at day 20.

  6. Effect of treatment on need for ICU stay at D60 [ Time Frame: Day 60 ]
    This outcome corresponds to the number of participants who need ICU stay at day 60.

  7. Effect of treatment on duration of ICU stay at D20 [ Time Frame: Day 20 ]
    This outcome evaluates the duration of patient's ICU stay at day 20.

  8. Effect of treatment on duration of ICU stay at D60 [ Time Frame: Day 60 ]
    This outcome evaluates the duration of patient's ICU stay at day 60.

  9. Effect of treatment on need of mechanical ventilation at D20 [ Time Frame: Day 20 ]
    This outcome corresponds to the number of participants who need mechanical ventilation at D20.

  10. Effect of treatment on need of mechanical ventilation at D60 [ Time Frame: Day 60 ]
    This outcome corresponds to the number of participants who need mechanical ventilation at D60.

  11. Effect of treatment on duration of mechanical ventilation at D20 [ Time Frame: Day 20 ]
    This outcome corresponds to the duration of patient's mechanical ventilation at D20.

  12. Effect of treatment on duration of mechanical ventilation at D60 [ Time Frame: Day 60 ]
    This outcome corresponds to the duration of patient's mechanical ventilation at D60.

  13. Effect of treatment on time to hospitalization at D20 [ Time Frame: Day 20 ]
    This outcome evaluates the delay between inclusion and hospitalization at D20.

  14. Effect of treatment on time to hospitalization at D60 [ Time Frame: Day 60 ]
    This outcome evaluates the delay between inclusion and hospitalization at D60.

  15. Effect of treatment on Duration of Hospital stay et D20 [ Time Frame: Day 20 ]
    This outcome evaluates the duration of patient's Hospital stay at D20.

  16. Effect of treatment on Duration of Hospital stay et D60 [ Time Frame: Day 60 ]
    This outcome evaluates the duration of patient's Hospital stay at D60.

  17. Effect of treatment on Duration of symptoms at D20 [ Time Frame: Day 20 ]
    This outcome evaluates the duration of symptoms at D20 after treatment.

  18. Effect of treatment on Duration of symptoms at D60 [ Time Frame: Day 60 ]
    This outcome evaluates the duration of symptoms at D60 after treatment.

  19. Incidence of Treatment-Emergent Adverse Events [ Time Frame: Month 6 ]
    This outcome measures the number of participants with treatment-related adverse events as assessed by CTCAE v4.0, at the end of study.


Other Outcome Measures:
  1. Effect of treatment on chest radiological features [ Time Frame: Month 6 ]
    This outcome evaluates the chest radiological features on Chest HRCT, at 6 months, after treatment.

  2. Effect of treatment on respiratory capacity [ Time Frame: Month 6 ]
    This outcome evaluates the Pulmonary function test at 6 month, after treatment.

  3. Cost consequence analysis [ Time Frame: Month 6 ]
    This ouctome eavaluates costs and consequences which will be presented for each stakeholder in a disaggregated way at the end of study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Either patients over 50 years of age with at least one comorbidity (hypertension, diabetes, obesity, cancer, chronic renal disease, immunodeficiency) OR patients over 70 years of age with or without comorbidity
  2. Laboratory (PCR-) proved infection by COVID-19 or radiological sign highly suggestive of COVID-19
  3. Respiratory symptoms (cough, chest discomfort, dyspnea)
  4. Affiliation to the social security network
  5. Able to understand and sign a written informed consent form

Exclusion Criteria:

  1. Need for hospitalization according to updated French guidelines (ministère de la santé_04/04/2020)
  2. Patient in long-term care facility
  3. Patient without concern confirmation of COVID-19 by laboratory (PCR swab) test or chest CT
  4. Known hypersensitivity or contra-indication to the 3 experimental treatments (azithromycin, hydroxychloroquine, lopinavir/ritonavir).
  5. Any reason making follow up of the patient impossible during the study period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04365582


Contacts
Layout table for location contacts
Contact: Helene Beaussier, MD PhD 1.44.12.78.83 ext 00 33 hbeaussier@hpsj.fr

Locations
Layout table for location information
France
Hôpital Privé d'Antony
Antony, France, 92160
Contact: Jean Marc NACCACHE, MD         
Principal Investigator: Jean Marc NACCACHE, MD         
Hôpital Avicenne
Bobigny, France, 93000
Contact: Hilario Nunes, MD       hilario.nunes@aphp.fr   
Principal Investigator: Hilario Nunes, MD         
Centre Hospitalier Intercommunal de Créteil
Créteil, France
Contact: Christos CHOUAID, MD       christos.chouaid@chicreteil.fr   
Principal Investigator: Christos CHOUAID, MD         
Groupe Hospitalier Paris Saint-Joseph
Paris, France, 75014
Contact: Jean-Marc Naccache, MD    1 44 12 67 47 ext 00 33    jmnaccache@hpsj.fr   
Institut Mutualiste Montsouris
Paris, France, 75014
Contact: Pierre CHARLES, MD       Pierre.charles@imm.fr   
Principal Investigator: Pierre CHARLES, MD         
Sponsors and Collaborators
Groupe Hospitalier Paris Saint Joseph
Investigators
Layout table for investigator information
Principal Investigator: Jean-Marc Naccache, MD Groupe Hospitalier Paris Saint Joseph
Publications:

Layout table for additonal information
Responsible Party: Groupe Hospitalier Paris Saint Joseph
ClinicalTrials.gov Identifier: NCT04365582    
Other Study ID Numbers: OUTCOV
First Posted: April 28, 2020    Key Record Dates
Last Update Posted: April 28, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Groupe Hospitalier Paris Saint Joseph:
COVID
outpatient
ambulatory
prognosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Ritonavir
Lopinavir
Azithromycin
Hydroxychloroquine
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Anti-Bacterial Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Antirheumatic Agents